Gallbladder Cancer Treatment Market Size, Share and Global Trend By Indication (Stage I, Stage II, Stage II, Stage IV), By Treatment (Radition Therapy, Chemotherapy, Immunotherapy, Others), By End User (Hospitals, Gynecology Clinics, Academic & Research Centers, Others) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Gallbladder cancer occurs when healthy cells in the gallbladder start growing rapidly, forming a mass called a tumor. A cancerous tumor is malignant, which can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the tissues of the gallbladder. The symptoms include jaundice pain, above the stomach, fever, nausea, and vomiting, bloating and lumps in the abdomen. Gallbladder cancer can be diagnosed by blood tests, ultrasound, CT scan, MRI, cholangiogram, angiography, and others.
Sedentary lifestyle, obesity and increasing consumption of tobacco and smoking are some of the major factors contributing to the increasing prevalence of gallbladder cancer globally. This combined with the introduction of new drugs by market players for the treatment of gallbladder cancer, are factors projected to fuel the demand, and drive the growth of the global gallbladder cancer treatment market during 2019-2026.
To gain extensive insights into the market, Request for Customization
However, lack of a comprehensive treatment method for gallbladder cancer, along with the longer duration of the treatment are some of the major factors deterring patients to undergo treatment, and in turn, restraining the growth of the global gallbladder cancer treatment market.
Key Players Covered
Some of the major companies that are present in the global gallbladder cancer treatment market are Boston Scientific Corporation, Intuitive Surgical, C. R. Bard, Inc., Dornier MedTech, Koninklijke Philips N.V., B. Braun Melsungen AG, Sanofi, and others. and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Indication | · Stage I · Stage II · Stage II · Stage IV |
By Treatment | · Radition Therapy · Chemotherapy · Immunotherapy · Others |
By End-User | · Hospitals · Gynecology Clinics · Academic & Research Centres · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
In 2018, among treatment type, chemotherpy therapy dominated the global gallbladder cancer treatment market due to introduction of new chemotherpy drugs in the market. This segment is projected to grow at comparatively higher CAGR during the forecast period.
Key Insights
- Epidemiology Gallbladder Cancer (Key Countries/Regions)
- The Economic Cost Burden of Gallbladder Cancer Treatment
- Pricing Analysis, By Treatment Type
- Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions
Regional Analysis
North America dominated the global gallbladder cancer treatment market in 2018. According to studies conduced by Centers for Disease Control and Prevention (CDC), about 3,700 people were suffering from gallbladder cancer. The increasing prevalence of gallbladder cancer is anticipated to increase the demand for the treatment susequnetly driving the growth of the global gallbladder cancer treatment market. This combined with a higher cost of the therapies in these countries and higher per capita healthcare expenditure are some of the factors responsible for a comparatively higher share of North America in the global gallbladder cancer treatment market in 2018. According to the American Cancer Society, an estimated 11,740 new cases of gallbladder cancer were diagnosed in 2017.
Key Industry Developments
- In May 2017, EMD Serono, Inc., recived US Food and Drug Administration (FDA) approval for the the immunotherapy drug Bavencio (avelumab) to treat people with advanced urothelial carcinoma, the most common type of bladder cancer.
- In May 2016, F. Hoffmann-La Roche Ltdn launched ew immunotherapy drug, atezolizumab, has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
